Optimer ligand why has nobody picked up on this6 Oct 2023 10:54
Optimer technology has been developed and commercialised by Aptamer Group, who are developing these affinity reagents as biotherapeutics and diagnostic tools.
Optimer therapeutics are being developed in partnership with Cancer Research UK that can selectively target a key gene fault for the treatment of Chronic Myelomonocytic Leukaemia (CMML) and other myeloid malignancies.[16]
Optimer conjugate therapies are being developed in partnership with AstraZeneca[22] and PinotBio.[14]
thats hugh news in its self surely and its 1p a share massive rise coming i think here
[LINK REMOVED]